| AFDCX | VFINX | AFDCX / VFINX | |
| Total Expense Ratio | 1.79 | 0.14 | 1,279% |
| Annual Report Gross Expense Ratio | 1.79 | 0.14 | 1,279% |
| Fund Existence | 21 years | 49 years | - |
| Gain YTD | -10.478 | 17.878 | -59% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 3.25B | 1.48T | 0% |
| Annual Yield % from dividends | 0.00 | 1.02 | - |
| Returns for 1 year | -12.86 | 14.85 | -87% |
| Returns for 3 years | 21.82 | 81.33 | 27% |
| Returns for 5 years | 22.42 | 87.47 | 26% |
| Returns for 10 years | 111.91 | 234.30 | 48% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| ARIHX | 6.97 | 0.01 | +0.14% |
| Aristotle Small/Mid Cap Equity I | |||
| MKVFX | 16.89 | 0.02 | +0.12% |
| MFS International Large Cap Value R3 | |||
| SCIUX | 12.33 | N/A | N/A |
| Invesco Income Advantage U.S. Fund R5 | |||
| MRIGX | 31.18 | -0.05 | -0.16% |
| Meridian Growth Investor | |||
| FBTCX | 29.33 | -0.74 | -2.46% |
| Fidelity Advisor Biotechnology C | |||